127 related articles for article (PubMed ID: 11249647)
1. Technology evaluation: TG-1031, Transgene SA.
Doehn C; Jocham D
Curr Opin Mol Ther; 2000 Feb; 2(1):106-11. PubMed ID: 11249647
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
3. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
4. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
5. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
6. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
7. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
8. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
[TBL] [Abstract][Full Text] [Related]
9. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
10. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
11. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
12. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.
Scholl SM; Balloul JM; Le Goc G; Bizouarne N; Schatz C; Kieny MP; von Mensdorff-Pouilly S; Vincent-Salomon A; Deneux L; Tartour E; Fridman W; Pouillart P; Acres B
J Immunother; 2000; 23(5):570-80. PubMed ID: 11001550
[TBL] [Abstract][Full Text] [Related]
13. TG-4010 Transgene.
Cohen S; Kaufman HL
Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Pantuck AJ; van Ophoven A; Gitlitz BJ; Tso CL; Acres B; Squiban P; Ross ME; Belldegrun AS; Figlin RA
J Immunother; 2004; 27(3):240-53. PubMed ID: 15076142
[TBL] [Abstract][Full Text] [Related]
15. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: Theratope, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):453-8. PubMed ID: 11249777
[TBL] [Abstract][Full Text] [Related]
17. MUC1 and breast cancer.
Apostolopoulos V; Pietersz GA; McKenzie IF
Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
[TBL] [Abstract][Full Text] [Related]
18. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12.
Mukherjee S; Upham JW; Ramshaw I; Bundell C; van Bruggen I; Robinson BW; Nelson DJ
Cancer Gene Ther; 2003 Aug; 10(8):591-602. PubMed ID: 12872141
[TBL] [Abstract][Full Text] [Related]
20. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.
Trevor KT; Hersh EM; Brailey J; Balloul JM; Acres B
Cancer Immunol Immunother; 2001 Oct; 50(8):397-407. PubMed ID: 11726134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
